Q3 2021 Investor Relations Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Kisqali® grew +27% in Q3; MONALEESA-2 OS results reinforcing
best-in-class profile
Sales evolution
USD bn, % cc
Ex-US
US
+27%
232
KisqaliⓇ well positioned to become first-choice CDK4/6i
☐
Only CDK4/6i with positive OS results in 3 Ph3 trials
■ MONALEESA-2 unprecedented OS results in largest segment
of aBC population
Continued growth acceleration, with share gains ex-US
■ Ex-US: Market leader in pre-menopausal setting in EU4 and UK
■ US demand in pre-menopausal and post-menopausal picking up
Moving forward with confidence in KisqaliⓇ and its unique profile
■ HARMONIA study to evaluate ribociclib vs. palbociclib in aggressive
HER2-enriched intrinsic subtype of HR+/HER2- ABC
■ NATALEE study in eBC completed enrollment in Q2 2021;
readout event-driven and expected end 2022
183
145
100
83
87
Q3 2020
Q3 2021
aBC advanced breast cancer eBC early breast cancer
34 Investor Relations | Q3 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation